Phase I/II study of oral WJ05129 in advanced solid tumors

Phase 2, open-label, single-arm trial of WJ05129 in Nonhematologic neoplasms, sponsored by Junjing Bio. Primary endpoints: Dose-limiting toxicities, adverse events, serious adverse events, clinically significant laboratory and other abnormal findings, maximum tolerated dose, and recommended phase II dose and Safety and tolerability including adverse events, serious adverse events, physical examination, ECOG performance status, laboratory tests, electrocardiogram, ophthalmic examination, vital signs, and… Started Sep 2022; status: terminated.